| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 18 | 2015 | 803 | 1.270 |
Why?
|
| Survivors | 7 | 2015 | 177 | 0.770 |
Why?
|
| Health Status Disparities | 3 | 2015 | 138 | 0.540 |
Why?
|
| Brain Neoplasms | 8 | 2015 | 649 | 0.510 |
Why?
|
| Rural Population | 3 | 2013 | 297 | 0.500 |
Why?
|
| Neoplasms | 5 | 2013 | 791 | 0.440 |
Why?
|
| Middle Aged | 45 | 2016 | 12703 | 0.440 |
Why?
|
| Aged | 39 | 2016 | 10998 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2013 | 489 | 0.380 |
Why?
|
| Female | 52 | 2016 | 21490 | 0.380 |
Why?
|
| Receptors, Estrogen | 2 | 2012 | 117 | 0.370 |
Why?
|
| Humans | 58 | 2017 | 34474 | 0.320 |
Why?
|
| Aged, 80 and over | 18 | 2016 | 4150 | 0.320 |
Why?
|
| Adult | 30 | 2016 | 10015 | 0.300 |
Why?
|
| Stroke | 6 | 2009 | 700 | 0.270 |
Why?
|
| Quality of Life | 9 | 2015 | 1032 | 0.270 |
Why?
|
| Depression | 4 | 2015 | 458 | 0.260 |
Why?
|
| Male | 37 | 2016 | 20697 | 0.260 |
Why?
|
| Cognition Disorders | 3 | 2015 | 390 | 0.260 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 28 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 1386 | 0.230 |
Why?
|
| Fatigue | 3 | 2015 | 90 | 0.230 |
Why?
|
| Lung Neoplasms | 2 | 2006 | 452 | 0.230 |
Why?
|
| Indans | 2 | 2015 | 36 | 0.220 |
Why?
|
| Brain Ischemia | 5 | 2009 | 160 | 0.220 |
Why?
|
| Piperidines | 2 | 2015 | 141 | 0.210 |
Why?
|
| Plant Extracts | 2 | 2017 | 64 | 0.210 |
Why?
|
| Adaptation, Psychological | 2 | 2015 | 145 | 0.200 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 183 | 0.200 |
Why?
|
| Coronary Disease | 3 | 2011 | 239 | 0.190 |
Why?
|
| Emergency Service, Hospital | 3 | 2011 | 502 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2014 | 1523 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2013 | 627 | 0.170 |
Why?
|
| Glioblastoma | 2 | 2015 | 161 | 0.170 |
Why?
|
| Glioma | 2 | 2014 | 138 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 214 | 0.170 |
Why?
|
| Obesity | 4 | 2013 | 1244 | 0.170 |
Why?
|
| Risk Factors | 11 | 2013 | 4136 | 0.170 |
Why?
|
| Thalidomide | 3 | 2011 | 34 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2013 | 174 | 0.160 |
Why?
|
| Body Composition | 2 | 2016 | 415 | 0.160 |
Why?
|
| Inpatients | 2 | 2011 | 88 | 0.160 |
Why?
|
| Health Promotion | 2 | 2012 | 264 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2011 | 1078 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2015 | 3618 | 0.140 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2015 | 42 | 0.140 |
Why?
|
| Chest Pain | 2 | 2011 | 232 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 274 | 0.140 |
Why?
|
| Double-Blind Method | 6 | 2017 | 597 | 0.140 |
Why?
|
| Radiotherapy | 2 | 2015 | 90 | 0.130 |
Why?
|
| Health Literacy | 2 | 2015 | 31 | 0.130 |
Why?
|
| Patient Preference | 2 | 2015 | 49 | 0.130 |
Why?
|
| Micronutrients | 1 | 2017 | 21 | 0.130 |
Why?
|
| Follow-Up Studies | 8 | 2015 | 2366 | 0.120 |
Why?
|
| Health Education | 2 | 2015 | 170 | 0.120 |
Why?
|
| European Continental Ancestry Group | 4 | 2015 | 1176 | 0.120 |
Why?
|
| Phytotherapy | 2 | 2017 | 41 | 0.120 |
Why?
|
| United States | 7 | 2013 | 4267 | 0.120 |
Why?
|
| African Americans | 2 | 2015 | 1435 | 0.120 |
Why?
|
| Electrocardiography | 3 | 2011 | 657 | 0.120 |
Why?
|
| Urban Population | 2 | 2013 | 97 | 0.120 |
Why?
|
| Head | 1 | 2016 | 58 | 0.110 |
Why?
|
| Connexin 43 | 1 | 2015 | 8 | 0.110 |
Why?
|
| Gap Junctions | 1 | 2015 | 9 | 0.110 |
Why?
|
| Benzhydryl Compounds | 1 | 2015 | 23 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 140 | 0.110 |
Why?
|
| Corn Oil | 1 | 2014 | 4 | 0.110 |
Why?
|
| Computer-Assisted Instruction | 1 | 2015 | 24 | 0.110 |
Why?
|
| User-Computer Interface | 1 | 2015 | 55 | 0.110 |
Why?
|
| Fish Oils | 1 | 2014 | 40 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2014 | 43 | 0.110 |
Why?
|
| Meningioma | 1 | 2015 | 59 | 0.110 |
Why?
|
| Health Behavior | 2 | 2013 | 246 | 0.110 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2015 | 95 | 0.110 |
Why?
|
| Taste Disorders | 1 | 2014 | 5 | 0.110 |
Why?
|
| Continental Population Groups | 2 | 2013 | 245 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 163 | 0.110 |
Why?
|
| Olfaction Disorders | 1 | 2014 | 8 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2013 | 260 | 0.100 |
Why?
|
| Saliva | 1 | 2014 | 41 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2015 | 203 | 0.100 |
Why?
|
| Ethnic Groups | 2 | 2013 | 483 | 0.100 |
Why?
|
| Internet | 2 | 2015 | 207 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2013 | 14 | 0.100 |
Why?
|
| Time Factors | 6 | 2015 | 2352 | 0.100 |
Why?
|
| Ubiquinone | 1 | 2013 | 8 | 0.100 |
Why?
|
| Social Welfare | 1 | 2012 | 4 | 0.100 |
Why?
|
| Colorectal Neoplasms | 2 | 2015 | 229 | 0.100 |
Why?
|
| Fatty Acids | 1 | 2013 | 108 | 0.090 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2012 | 27 | 0.090 |
Why?
|
| Vitamins | 1 | 2013 | 75 | 0.090 |
Why?
|
| Exercise | 4 | 2013 | 700 | 0.090 |
Why?
|
| Ginkgo biloba | 1 | 2012 | 20 | 0.090 |
Why?
|
| Ochratoxins | 1 | 2012 | 1 | 0.090 |
Why?
|
| Mood Disorders | 1 | 2012 | 22 | 0.090 |
Why?
|
| Hydroquinones | 1 | 2012 | 7 | 0.090 |
Why?
|
| Mutagens | 1 | 2012 | 7 | 0.090 |
Why?
|
| Plant Preparations | 1 | 2012 | 29 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2015 | 801 | 0.090 |
Why?
|
| Young Adult | 6 | 2016 | 2825 | 0.090 |
Why?
|
| Feasibility Studies | 4 | 2015 | 323 | 0.090 |
Why?
|
| Panax | 1 | 2012 | 9 | 0.090 |
Why?
|
| Family | 1 | 2012 | 123 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 20 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2012 | 135 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 42 | 0.090 |
Why?
|
| Procarbazine | 1 | 2011 | 6 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2012 | 953 | 0.090 |
Why?
|
| Stearoyl-CoA Desaturase | 1 | 2011 | 15 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 40 | 0.090 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2011 | 36 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 51 | 0.090 |
Why?
|
| Patient Admission | 1 | 2011 | 59 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 36 | 0.080 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2010 | 2 | 0.080 |
Why?
|
| Amenorrhea | 1 | 2010 | 6 | 0.080 |
Why?
|
| Menstruation | 1 | 2010 | 6 | 0.080 |
Why?
|
| Dystrophin | 1 | 2010 | 4 | 0.080 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2010 | 3 | 0.080 |
Why?
|
| Isometric Contraction | 1 | 2010 | 28 | 0.080 |
Why?
|
| Myocardial Ischemia | 2 | 2008 | 114 | 0.080 |
Why?
|
| Smoking | 2 | 2013 | 544 | 0.080 |
Why?
|
| Health Status | 1 | 2012 | 411 | 0.080 |
Why?
|
| Community Health Services | 1 | 2010 | 50 | 0.080 |
Why?
|
| Heart Diseases | 1 | 2011 | 124 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2010 | 74 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 136 | 0.080 |
Why?
|
| Genome, Human | 2 | 2008 | 136 | 0.080 |
Why?
|
| Nervous System Diseases | 2 | 2008 | 47 | 0.080 |
Why?
|
| Enteral Nutrition | 1 | 2010 | 30 | 0.080 |
Why?
|
| Comorbidity | 1 | 2011 | 596 | 0.080 |
Why?
|
| Carboplatin | 2 | 2006 | 55 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2010 | 31 | 0.080 |
Why?
|
| Diet | 2 | 2012 | 418 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2010 | 120 | 0.080 |
Why?
|
| Diet, Reducing | 1 | 2010 | 109 | 0.080 |
Why?
|
| Health Services | 1 | 2010 | 42 | 0.080 |
Why?
|
| Incidence | 5 | 2012 | 1288 | 0.080 |
Why?
|
| Dietary Supplements | 3 | 2017 | 197 | 0.080 |
Why?
|
| Triage | 1 | 2010 | 76 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2012 | 360 | 0.070 |
Why?
|
| Prognosis | 5 | 2013 | 1603 | 0.070 |
Why?
|
| Age Factors | 4 | 2013 | 1261 | 0.070 |
Why?
|
| Mass Screening | 1 | 2011 | 268 | 0.070 |
Why?
|
| Brain | 1 | 2016 | 1031 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2011 | 3812 | 0.070 |
Why?
|
| Echocardiography, Stress | 1 | 2008 | 28 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2013 | 1607 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2008 | 36 | 0.070 |
Why?
|
| Personnel Selection | 1 | 2008 | 16 | 0.070 |
Why?
|
| Exercise Therapy | 1 | 2010 | 283 | 0.070 |
Why?
|
| Case-Control Studies | 4 | 2014 | 924 | 0.070 |
Why?
|
| Informed Consent | 1 | 2008 | 45 | 0.070 |
Why?
|
| Urodynamics | 1 | 2008 | 88 | 0.070 |
Why?
|
| Urination | 1 | 2008 | 69 | 0.070 |
Why?
|
| Methylphenidate | 1 | 2007 | 39 | 0.070 |
Why?
|
| Lymphedema | 1 | 2007 | 5 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 356 | 0.060 |
Why?
|
| Topotecan | 1 | 2006 | 18 | 0.060 |
Why?
|
| Cohort Studies | 5 | 2009 | 1910 | 0.060 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 85 | 0.060 |
Why?
|
| Prospective Studies | 5 | 2011 | 2461 | 0.060 |
Why?
|
| Etoposide | 1 | 2006 | 42 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2008 | 268 | 0.060 |
Why?
|
| Medical Records | 1 | 2006 | 81 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 185 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 119 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2008 | 320 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2008 | 440 | 0.050 |
Why?
|
| Logistic Models | 3 | 2013 | 808 | 0.050 |
Why?
|
| Premenopause | 3 | 2010 | 55 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2011 | 934 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 849 | 0.050 |
Why?
|
| Survival Rate | 3 | 2012 | 925 | 0.050 |
Why?
|
| Memory | 2 | 2015 | 216 | 0.050 |
Why?
|
| Social Support | 2 | 2015 | 195 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 231 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 589 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1209 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 372 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2013 | 310 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2015 | 583 | 0.050 |
Why?
|
| Prevalence | 3 | 2010 | 1034 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2015 | 772 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2012 | 922 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 628 | 0.040 |
Why?
|
| Affect | 2 | 2015 | 72 | 0.040 |
Why?
|
| Linear Models | 2 | 2013 | 464 | 0.040 |
Why?
|
| Costs and Cost Analysis | 2 | 2012 | 113 | 0.040 |
Why?
|
| Acute Disease | 2 | 2012 | 276 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 446 | 0.040 |
Why?
|
| Child | 3 | 2012 | 2613 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 399 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2013 | 212 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2013 | 240 | 0.040 |
Why?
|
| Animals | 4 | 2015 | 8544 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 3799 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 508 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 755 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 350 | 0.030 |
Why?
|
| Forecasting | 2 | 2010 | 153 | 0.030 |
Why?
|
| North Carolina | 2 | 2012 | 1612 | 0.030 |
Why?
|
| Powders | 1 | 2017 | 9 | 0.030 |
Why?
|
| Sex Factors | 2 | 2011 | 707 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 803 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2017 | 32 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 34 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2016 | 17 | 0.030 |
Why?
|
| Antioxidants | 1 | 2017 | 126 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2691 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2016 | 52 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2015 | 96 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 74 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2015 | 53 | 0.030 |
Why?
|
| Cell Communication | 1 | 2015 | 42 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 84 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2011 | 1506 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2015 | 71 | 0.030 |
Why?
|
| Myocardial Infarction | 2 | 2010 | 515 | 0.030 |
Why?
|
| Learning | 1 | 2015 | 88 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 214 | 0.030 |
Why?
|
| Salivary Proteins and Peptides | 1 | 2014 | 4 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2015 | 82 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 31 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 103 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 45 | 0.030 |
Why?
|
| Life Change Events | 1 | 2013 | 21 | 0.030 |
Why?
|
| Ergocalciferols | 1 | 2013 | 4 | 0.030 |
Why?
|
| National Health Programs | 1 | 2013 | 6 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2015 | 545 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 819 | 0.020 |
Why?
|
| Spirituality | 1 | 2013 | 38 | 0.020 |
Why?
|
| Hypercalcemia | 1 | 2013 | 13 | 0.020 |
Why?
|
| Psychology | 1 | 2013 | 25 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 273 | 0.020 |
Why?
|
| Specialization | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 28 | 0.020 |
Why?
|
| Taxoids | 1 | 2013 | 60 | 0.020 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2012 | 13 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 185 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 61 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2016 | 365 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 176 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 74 | 0.020 |
Why?
|
| Lac Operon | 1 | 2012 | 7 | 0.020 |
Why?
|
| RNA, Transfer | 1 | 2012 | 3 | 0.020 |
Why?
|
| Genes, Suppressor | 1 | 2012 | 3 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2013 | 191 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2012 | 11 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2012 | 44 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 170 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 529 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 265 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 70 | 0.020 |
Why?
|
| Plasmids | 1 | 2012 | 52 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 90 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2013 | 129 | 0.020 |
Why?
|
| Patient Participation | 1 | 2013 | 93 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 480 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 267 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2012 | 138 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2012 | 92 | 0.020 |
Why?
|
| Models, Economic | 1 | 2011 | 21 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2011 | 14 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 26 | 0.020 |
Why?
|
| Cost Savings | 1 | 2011 | 38 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 41 | 0.020 |
Why?
|
| Drug Costs | 1 | 2011 | 51 | 0.020 |
Why?
|
| Adenosine | 1 | 2011 | 74 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 576 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 159 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 485 | 0.020 |
Why?
|
| Dobutamine | 1 | 2011 | 71 | 0.020 |
Why?
|
| Cell Line | 1 | 2012 | 476 | 0.020 |
Why?
|
| Otitis Media | 1 | 2011 | 24 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 222 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 288 | 0.020 |
Why?
|
| Life Style | 1 | 2013 | 418 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 235 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 984 | 0.020 |
Why?
|
| Protestantism | 1 | 2010 | 8 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2010 | 19 | 0.020 |
Why?
|
| Heterozygote | 1 | 2010 | 66 | 0.020 |
Why?
|
| Counseling | 1 | 2010 | 99 | 0.020 |
Why?
|
| Physical Endurance | 1 | 2010 | 42 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2010 | 54 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 509 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 130 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2010 | 97 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2011 | 86 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 16 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2010 | 18 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2011 | 214 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 69 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2010 | 139 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 249 | 0.020 |
Why?
|
| Safety Management | 1 | 2010 | 33 | 0.020 |
Why?
|
| Glasgow Outcome Scale | 1 | 2009 | 3 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2009 | 16 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 197 | 0.020 |
Why?
|
| Cerebral Infarction | 1 | 2009 | 25 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2009 | 131 | 0.020 |
Why?
|
| Seasons | 1 | 2009 | 94 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2010 | 190 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 352 | 0.020 |
Why?
|
| Exercise Test | 1 | 2010 | 247 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 168 | 0.020 |
Why?
|
| Angina, Unstable | 1 | 2008 | 22 | 0.020 |
Why?
|
| North America | 1 | 2008 | 34 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 262 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2008 | 32 | 0.020 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 210 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2007 | 28 | 0.020 |
Why?
|
| Rats | 1 | 2012 | 1946 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 79 | 0.020 |
Why?
|
| Language | 1 | 2007 | 45 | 0.020 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2008 | 109 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 168 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 128 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2007 | 24 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2007 | 63 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2008 | 155 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 565 | 0.020 |
Why?
|
| Weight Gain | 1 | 2008 | 117 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 304 | 0.020 |
Why?
|
| Hospitalization | 1 | 2010 | 500 | 0.020 |
Why?
|
| Arm | 1 | 2007 | 43 | 0.020 |
Why?
|
| Siblings | 1 | 2006 | 24 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2006 | 52 | 0.020 |
Why?
|
| Hand | 1 | 2007 | 80 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2006 | 73 | 0.020 |
Why?
|
| Alleles | 1 | 2007 | 257 | 0.020 |
Why?
|
| Camptothecin | 1 | 2006 | 52 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 156 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2008 | 484 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 133 | 0.020 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 367 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2008 | 186 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 343 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 568 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 1354 | 0.010 |
Why?
|
| Genotype | 1 | 2007 | 743 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 439 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 1024 | 0.010 |
Why?
|